دورية أكاديمية
أعرض في EDS

Monocyte infiltration is an independent positive prognostic biomarker in vulvar squamous cell carcinoma.

التفاصيل البيبلوغرافية
العنوان: Monocyte infiltration is an independent positive prognostic biomarker in vulvar squamous cell carcinoma.
المؤلفون: Abdulrahman Z; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands., Kortekaas KE; Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands., Welters MJP; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands., van Poelgeest MIE; Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands., van der Burg SH; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. shvdburg@lumc.nl.
المصدر: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Jul 02; Vol. 73 (9), pp. 166. Date of Electronic Publication: 2024 Jul 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York, NY : Springer International, c1982-
مواضيع طبية MeSH: Vulvar Neoplasms*/immunology , Vulvar Neoplasms*/pathology , Vulvar Neoplasms*/mortality , Vulvar Neoplasms*/therapy , Carcinoma, Squamous Cell*/immunology , Carcinoma, Squamous Cell*/pathology , Carcinoma, Squamous Cell*/mortality , Carcinoma, Squamous Cell*/therapy , Biomarkers, Tumor* , Monocytes*/immunology, Humans ; Female ; Prognosis ; Middle Aged ; Aged ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/metabolism ; Adult ; Aged, 80 and over
مستخلص: Background: Vulvar squamous cell carcinoma (VSCC) arises after an HPV infection or the mutation of p53 or other driver genes and is treated by mutilating surgery and/or (chemo) radiation, with limited success and high morbidity. In-depth information on the immunological make up of VSCC is pivotal to assess whether immunotherapy may form an alternative treatment.
Methods: A total of 104 patient samples, comprising healthy vulva (n = 27) and VSCC (n = 77), were analyzed. Multispectral immunofluorescence (15 markers) was used to study both the myeloid and lymphoid immune cell composition, and this was linked to differences in transcriptomics (NanoString nCounter, 1258 genes) and in survival (Kaplan-Meier analyses).
Results: Healthy vulva and VSCC are both well infiltrated but with different subpopulations of lymphoid and myeloid cells. In contrast to the lymphoid cell infiltrate, the density and composition of the myeloid cell infiltrate strongly differed per VSCC molecular subtype. A relative strong infiltration with epithelial monocytes (HLADR - CD11c - CD14 + CD68 - CD163 - CD33 - ) was prognostic for improved survival, independent of T cell infiltration, disease stage or molecular subtype. A strong infiltration with T cells and/or monocytes was associated with drastic superior survival: 5-year survival > 90% when either one is high, versus 40% when both are low (p < 0.001).
Conclusion: A hot myeloid and/or lymphoid infiltrate predicts excellent survival in VSCC. Based on the response of similarly high-infiltrated other tumor types, we have started to explore the potential of neoadjuvant checkpoint blockade in VSCC.
(© 2024. The Author(s).)
References: Nature. 2018 Feb 22;554(7693):544-548. (PMID: 29443960)
Bioinformatics. 2009 Apr 15;25(8):1091-3. (PMID: 19237447)
Expert Opin Biol Ther. 2018 Dec;18(12):1223-1233. (PMID: 30373410)
J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34716208)
Cancer Res. 2009 Mar 15;69(6):2685-93. (PMID: 19258510)
Nature. 2014 Nov 27;515(7528):568-71. (PMID: 25428505)
J Immunother Cancer. 2019 Sep 3;7(1):236. (PMID: 31481117)
Immunity. 2006 Feb;24(2):191-201. (PMID: 16473831)
Lab Invest. 2017 Nov;97(11):1296-1305. (PMID: 28759013)
J Clin Invest. 2020 Feb 3;130(2):774-788. (PMID: 31661470)
Cancer Discov. 2016 Feb;6(2):202-16. (PMID: 26645196)
Nat Rev Immunol. 2018 Oct;18(10):635-647. (PMID: 30057419)
J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32169871)
J Immunother Cancer. 2019 Nov 8;7(1):295. (PMID: 31703593)
Arthritis Rheumatol. 2017 Apr;69(4):826-836. (PMID: 27863141)
Cancer Cell. 2023 Jul 10;41(7):1222-1241.e7. (PMID: 37433281)
Nat Med. 2018 Feb;24(2):165-175. (PMID: 29309058)
Nat Genet. 2003 Jul;34(3):267-73. (PMID: 12808457)
Immunity. 2018 Apr 17;48(4):812-830.e14. (PMID: 29628290)
Cancer Res. 2016 Oct 15;76(20):6118-6129. (PMID: 27530326)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
J Hematol Oncol. 2019 Nov 27;12(1):125. (PMID: 31775797)
J Immunother Cancer. 2022 Feb;10(2):. (PMID: 35217577)
Nat Med. 2018 Nov;24(11):1649-1654. (PMID: 30297909)
Clin Cancer Res. 2017 Nov 15;23(22):6781-6789. (PMID: 28899974)
Nature. 2019 Aug;572(7770):538-542. (PMID: 31367040)
Curr Top Microbiol Immunol. 2011;344:1-24. (PMID: 20512556)
Int J Gynecol Pathol. 2006 Jan;25(1):30-7. (PMID: 16306781)
Int J Cancer. 2020 Nov 15;147(10):2914-2923. (PMID: 32574376)
J Pathol. 2002 Oct;198(2):258-69. (PMID: 12237887)
Nature. 2015 Jul 9;523(7559):231-5. (PMID: 25970248)
فهرسة مساهمة: Keywords: Immunotherapy; Prognostic biomarker; Tumor immune microenvironment; Vulvar squamous cell carcinoma
المشرفين على المادة: 0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20240702 Date Completed: 20240702 Latest Revision: 20240814
رمز التحديث: 20240814
مُعرف محوري في PubMed: PMC11219697
DOI: 10.1007/s00262-024-03755-w
PMID: 38954042
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0851
DOI:10.1007/s00262-024-03755-w